- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024€19.79 (-1.44%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024€19.25 (+2.39%)Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023€18 (+0.28%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023€24.5 (-2.93%)Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023€22.18 (+8.83%)Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023€25.98 (-1.44%)Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022€22.26 (-3.13%)Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022€7.27 (-1.96%)Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022€7.27 (-3.00%)Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022€10.4 (+0.39%)Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021€14.5 (+2.26%)Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021€14.02 (-1.54%)Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021€8.79 (-2.55%)Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021€9.84 (+0.51%)Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020€8.31 (+0.12%)Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020€7.07 (-1.74%)Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020€5.99 (-7.99%)Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020€8 (-0.37%)Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019€8.29 (-1.31%)Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019€6.7 (-0.89%)Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019€6.88 (+2.23%)Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019€9.01 (+0.45%)Earnings
Q2 2022 BioArctic AB Earnings Call Transcript
Good morning, and welcome to the Q2 2022 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Gunilla Osswald, CEO. Please go ahead.
()-
Thank you. Good morning, and welcome to BioArctic's presentation from the second quarter. I'm Gunilla Osswald, and I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson. I will give an update on lecanemab and some recent highlights. Lecanemab is progressing really well, and the marketing application for an accelerated approval has been accepted by the FDA, and they have granted a priority review.
I think it looks very promising for lecanemab, and it's a very exciting time for us with the Phase III readout of the Clarity AD study coming closer. And we also have a potential for an accelerated approval in the U.S. within 6 months. I will, of course, talk more about that here today.
Next slide, please. BioArctic is listed at Nasdaq
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)